Astrazeneca PLC (NYSE:AZN) had its price objective boosted by analysts at Leerink Swann from $31.00 to $34.00 in a research report issued to clients and investors on Monday. The brokerage currently has a “market perform” rating on the stock. Leerink Swann’s target price suggests a potential downside of 1.13% from the company’s previous close.

Several other research firms also recently commented on AZN. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Friday, September 22nd. Investec upgraded shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Barclays PLC reiterated an “overweight” rating on shares of Astrazeneca PLC in a research report on Monday, July 3rd. Argus reiterated a “buy” rating and set a $35.00 target price on shares of Astrazeneca PLC in a research report on Friday, September 1st. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating on shares of Astrazeneca PLC in a research report on Thursday, July 13th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $35.10.

Astrazeneca PLC (NYSE AZN) traded down 0.66% during midday trading on Monday, hitting $34.39. 2,574,980 shares of the company were exchanged. The stock has a market capitalization of $87.08 billion, a PE ratio of 22.56 and a beta of 0.76. The firm’s 50-day moving average price is $33.41 and its 200-day moving average price is $32.38. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60.

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. During the same period last year, the company earned $0.83 EPS. The firm’s revenue was down 9.9% compared to the same quarter last year. Equities research analysts anticipate that Astrazeneca PLC will post $1.91 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Astrazeneca PLC (AZN) Price Target Increased to $34.00 by Analysts at Leerink Swann” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/astrazeneca-plc-azn-price-target-increased-to-34-00-by-analysts-at-leerink-swann.html.

A number of hedge funds have recently made changes to their positions in the business. Fisher Asset Management LLC increased its stake in Astrazeneca PLC by 4.7% during the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares in the last quarter. BlackRock Inc. increased its stake in Astrazeneca PLC by 287,844.0% during the 1st quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock valued at $215,198,000 after purchasing an additional 6,908,257 shares in the last quarter. Federated Investors Inc. PA increased its stake in Astrazeneca PLC by 3.6% during the 2nd quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock valued at $152,885,000 after purchasing an additional 156,256 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Astrazeneca PLC by 5.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,827,262 shares of the company’s stock valued at $96,789,000 after purchasing an additional 157,293 shares in the last quarter. Finally, Voya Investment Management LLC increased its stake in Astrazeneca PLC by 38.2% during the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after purchasing an additional 662,481 shares in the last quarter. Institutional investors and hedge funds own 14.17% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.